Developing targeted peptides to fight infections and cancer
Official title: Dual protease activated peptides for specific targeting
Funded at University of California, San Francisco · NIH-10888899 · Data updated 2026-11-12
This study is working on new treatments that use special proteins to find and destroy bad cells like bacteria and cancer, while keeping healthy cells safe, so patients can have better and safer options for their care.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $74,284 |
| NIH project number | 5F32GM150255-02 |
| Project ID | NIH-10888899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with bacterial infections or specific types of cancer that may benefit from targeted peptide therapies.
✕Less likely to help
Patients with conditions unrelated to bacterial infections or cancer may not receive any benefit from this research.
What this research studies
This research focuses on creating specialized peptides that can selectively target and kill harmful cells, such as bacteria and cancer cells, while minimizing damage to healthy cells. The approach involves designing prodrugs that are activated by specific enzymes, allowing for precise control over their activity. By modifying the structure of these peptides, the researchers aim to enhance their effectiveness and reduce side effects. Patients may benefit from new treatments that are more effective and safer than current options.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for infections and certain cancers.
How similar studies have gone: Other research has shown promise in using protease-activated peptides for targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Tackie-Yarboi, Ethel Naa Odey — University of California, San Francisco
- Study coordinator: Tackie-Yarboi, Ethel Naa Odey
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.